Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Thyroglobulin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Thyroglobulin. Displaying page 1 of 1.
    EudraCT Number: 2007-002365-13 Sponsor Protocol Number: IMP 12791 Start Date*: 2007-06-29
    Sponsor Name:Bayer B.V.
    Full Title: Sorafenib as adjuvant to radioiodine therapy in non-medullary thyroid carcinoma
    Medical condition: non-medullary thyroid carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005242-21 Sponsor Protocol Number: 07_ENDO_66 Start Date*: 2008-05-07
    Sponsor Name:THE CHRISTIE NHS FOUNDATION TRUST
    Full Title: A pilot study of replacement therapy with recombinant TSH in central hypothyroidism
    Medical condition: Central Hypothyroidism which is due to deficiency of TSH caused by the disease, surgery or radiotherapy of the pituitary gland.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-002614-36 Sponsor Protocol Number: 05ICHF/T407 Start Date*: 2007-04-20
    Sponsor Name:IBSA
    Full Title: Multicentre, controlled, randomised, open-label, cross-over clinical study of the efficacy and tolerability of L-thyroxine T4 soft capsules, in comparison to L-thyroxine tablets, in thyroidectomi...
    Medical condition: Substitutive and/or TSH suppressive therapy in thyroidectomized patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021117 Hypothyroidism postoperative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006220-40 Sponsor Protocol Number: 2022-0101-01 Start Date*: 2022-06-30
    Sponsor Name:Hvidovre Hospital, Department of Gynecology
    Full Title: Double-blinded randomized placebo-controlled trial on tacrolimus in women with an euploid pregnancy loss and PCOS and/or thyroid autoimmunity
    Medical condition: Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10065161 Polycystic ovarian syndrome LLT
    21.0 100000004848 10069094 Thyroid peroxidase antibody positive LLT
    20.1 100000004848 10060326 Thyroglobulin antibody positive LLT
    22.1 100000004868 10072314 Pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003677-25 Sponsor Protocol Number: 12I/T405 Start Date*: 2013-01-27
    Sponsor Name:IBSA INSTITUT BIOCHIMIQUE SA
    Full Title: Safety and bioavailability of Tirosint (Levothyroxine Sodium) Oral Solution administered as single dose with or without water in hypothyroid patients.
    Medical condition: Both genders thyroidectomized patients, with thyroglobulin (Tg) circulating levels below 5 ng/mL and no evidence of Tg antibodies (Tg-Ab), at stable (at least 3 months) 100 μg/day levothyroxine ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10021114 Hypothyroidism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016669-27 Sponsor Protocol Number: P10- Start Date*: 2010-04-14
    Sponsor Name:Leiden University Medical Center
    Full Title: A phase II study to investigate the efficacy of RAD001 (Afinitor®, everolimus) in patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyr...
    Medical condition: Patients with irresectable recurrent or metastatic differentiated, undifferentiated (anaplastic) and medullary thyroid carcinoma will be treated in a phase II study to investigate the efficacy of R...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002968-27 Sponsor Protocol Number: INTERMEDIATE-01 Start Date*: 2020-02-18
    Sponsor Name:Centre François Baclesse
    Full Title: Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration (3.7 GBq I131 after rhTSH) versus decision o...
    Medical condition: Differentiated thyroid cancer - subgroup of patients with intermediate risk of postoperative residual disease
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002941-49 Sponsor Protocol Number: ERRITI Start Date*: 2017-01-31
    Sponsor Name:University Hospital Essen (Anstalt des öffentlichen Rechts)
    Full Title: Enhancing Radioiodine Incorporation into Radio Iodine Refractory Thyroid Cancers with MAPK Inhibition: A single center pilot study
    Medical condition: Radio Iodine Refractory Thyroid Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001771-21 Sponsor Protocol Number: XL184–311 Start Date*: Information not available in EudraCT
    Sponsor Name:Exelixis, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-...
    Medical condition: Radioiodine-Refractory Differentiated Thyroid Cancer which has progressed after prior VEGFR-targeted therapy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) FR (Completed) AT (Prematurely Ended) HU (Completed) ES (Ongoing) PL (Trial now transitioned) CZ (Completed) HR (Completed) GB (GB - no longer in EU/EEA) IT (Completed) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004450-27 Sponsor Protocol Number: THYR01605 Start Date*: 2006-05-02
    Sponsor Name:GENZYME
    Full Title: Follow-up of Thyroid Cancer Patients from Study THYR-008-00 Who Received Thyroid Remnant Ablation Using Either the Hypothyroid or the Thyrogen Method
    Medical condition: Follow-up of Thyroid Cancer Patients from Study THYR-008-00
    Disease: Version SOC Term Classification Code Term Level
    6.1 10043738 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005933-12 Sponsor Protocol Number: E7080-G000-201 Start Date*: 2009-10-29
    Sponsor Name:Eisai Limited
    Full Title: Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified...
    Medical condition: Medullary thyroid cancer [MTC] or radioiodine (131*I) refractory/resistant differentiated thyroid cancer[DTC]: Determine the pharmacokinetic (PK) profile and the pharmacokinetic/pharmacodynamic (PK...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065252 Solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001066-42 Sponsor Protocol Number: GETNE-T1812 Start Date*: 2020-02-20
    Sponsor Name:Spanish Group of Neuroendocrine Tumors (GETNE)
    Full Title: A phase II study of durvalumab (MEDI4736) plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma - The DUTHY trial
    Medical condition: Advanced, radioiodine-refractory differentiated thyroid carcinoma, including papillary, follicular, Hürtle Cell and poorly-differentiated thyroid carcinoma (DTC). Advanced medullary thyroid carcino...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10076603 Poorly differentiated thyroid carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002240 Anaplastic thyroid cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071027 Thyroid cancer stage I PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071028 Thyroid cancer stage II PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-003814-15 Sponsor Protocol Number: 2012-784 Start Date*: 2013-03-06
    Sponsor Name:HOSPICES CIVILS DE LYON
    Full Title: A multicenter phase II pilot open label study to evaluate the efficacy and safety of BKM120 in the treatment of patients with advanced or metastatic differentiated thyroid cancers
    Medical condition: Follicular or poorly differentiated cancer refractory to radio iodine
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005199-27 Sponsor Protocol Number: E7080-G000-211 Start Date*: Information not available in EudraCT
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With 131I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily W...
    Medical condition: 131I-refractory differentiated thyroid cancer (DTC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) DK (Prematurely Ended) ES (Prematurely Ended) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002507-34 Sponsor Protocol Number: GSN000200 Start Date*: 2014-02-20
    Sponsor Name:Genkyotex Innovation SAS
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria
    Medical condition: Patients with type 2 diabetes and albuminuria.
    Disease: Version SOC Term Classification Code Term Level
    17.0 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    17.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    17.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-000742-21 Sponsor Protocol Number: 2017/2527 Start Date*: 2017-07-31
    Sponsor Name:Gustave Roussy
    Full Title: Efficacy of a selective MEK (trametinib) and BRAFV600E (dabrafenib) inhibitors associated with radioactive iodine (RAI) for the treatment of refractory metastatic differentiated thyroid cancer with...
    Medical condition: Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients with RAS or BRAF mutation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016935 Follicular thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066474 Thyroid cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033701 Papillary thyroid cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004676-35 Sponsor Protocol Number: RVT-1401-2001 Start Date*: 2019-10-23
    Sponsor Name:Immunovant Sciences GmbH
    Full Title: ASCEND GO2: A Phase 2b, Multicenter, Randomized, Double-blind, Placebo-controlled Study of RVT-1401 for the Treatment of Patients with Active, Moderate to Severe Graves’ Ophthalmopathy
    Medical condition: Graves´Ophthalmopathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004853 10057889 Graves' ophthalmopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000800-59 Sponsor Protocol Number: LOXO-RET-17001 Start Date*: 2019-02-22
    Sponsor Name:Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
    Full Title: A Phase 1/2 Study of Oral LOXO-292 in Patients with Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors with RET Activation (LIBRETTO-001)
    Medical condition: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027105 Medullary thyroid cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) NL (Ongoing) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:08:16 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA